J Henricus Van Krieken

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6273947/publications.pdf

Version: 2024-02-01

165 papers	9,939 citations	71102 41 h-index	36028 97 g-index
167 all docs	167 docs citations	167 times ranked	15589 citing authors

#	Article	IF	Citations
1	Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell Lymphoma. Clinical Cancer Research, 2022, 28, 972-983.	7.0	22
2	Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents. Molecular Cancer Research, 2021, 19, 249-260.	3.4	20
3	e-Learning for Instruction and to Improve Reproducibility of Scoring Tumor-Stroma Ratio in Colon Carcinoma: Performance and Reproducibility Assessment in the UNITED Study. JMIR Formative Research, 2021, 5, e19408.	1.4	9
4	Daily practice in guideline adherence to adjuvant chemotherapy in stage III colon cancer and predictors of outcome. European Journal of Surgical Oncology, 2021, 47, 2060-2068.	1.0	3
5	Tumour-stroma ratio outperforms tumour budding as biomarker in colon cancer: a cohort study. International Journal of Colorectal Disease, 2021, 36, 2729-2737.	2.2	8
6	Memento for interprofessional learning. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 477, 755-756.	2.8	1
7	High frequency of inactivating tetraspanin CD37 mutations in diffuse large B-cell lymphoma at immune-privileged sites. Blood, 2019, 134, 946-950.	1.4	18
8	Neoplastic cell percentage estimation in tissue samples for molecular oncology: recommendations from a modified Delphi study. Histopathology, 2019, 75, 312-319.	2.9	15
9	Uniform Noting for International Application of the Tumor-Stroma Ratio as an Easy Diagnostic Tool: Protocol for a Multicenter Prospective Cohort Study. JMIR Research Protocols, 2019, 8, e13464.	1.0	20
10	The tumourâ€“stroma ratio in colon cancer: the biological role and its prognostic impact. Histopathology, 2018, 73, 197-206.	2.9	97
11	External Quality Assessment Identifies Training Needs to Determine the Neoplastic Cell Content for Biomarker Testing. Journal of Molecular Diagnostics, 2018, 20, 455-464.	2.8	16
12	RAS testing for colorectal cancer patients is reliable in European laboratories that pass external quality assessment. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 472, 717-725.	2.8	7
13	Detection of EGFR Variants in Plasma. Journal of Molecular Diagnostics, 2018, 20, 483-494.	2.8	37
14	Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy. Leukemia, 2018, 32, 353-363.	7.2	36
15	Scoring the tumor-stroma ratio in colon cancer: procedure and recommendations. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 473, 405-412.	2.8	113
16	Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma. Neoplasia, 2018, 20, 574-593.	5.3	64
17	A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Modern Pathology, 2018, 31, 1770-1786.	5.5	739
18	Accreditation, setting and experience as indicators to assure quality in oncology biomarker testing laboratories. British Journal of Cancer, 2018, 119, 605-614.	6.4	21

#	Article	IF	Citations
19	Recurrent mutations in genes involved in nuclear factorâ€ºB signalling in nodal marginal zone lymphomaâ€"diagnostic and therapeutic implications. Histopathology, 2017, 70, 174-184.	2.9	21
20	AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma. American Journal of Pathology, 2017, 187, 1700-1716.	3.8	39
21	Hepatitis C virus positive diffuse large B-cell lymphomas have distinct molecular features and lack BCL2 translocations. British Journal of Cancer, 2017, 117, 1685-1688.	6.4	13
22	Novel developments in the pathogenesis and diagnosis of extranodal marginal zone lymphoma. Journal of Hematopathology, 2017, 10, 91-107.	0.4	45
23	New developments in the pathology of malignant lymphoma: a review of the literature published from May to August 2017. Journal of Hematopathology, 2017, 10, 65-73.	0.4	8
24	Unraveling genetic predisposition to familial or early onset gastric cancer using germline whole-exome sequencing. European Journal of Human Genetics, 2017, 25, 1246-1252.	2.8	34
25	Quality in pathology. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 471, 311-312.	2.8	0
26	New developments in the pathology of malignant lymphoma: a review of the literature published from January to April 2017. Journal of Hematopathology, 2017, 10, 25-33.	0.4	3
27	Will the liquid biopsy replace traditional hematopathology?. Journal of Hematopathology, 2017, 10, 1-1.	0.4	0
28	RAS mutation prevalence among patients with metastatic colorectal cancer: a meta-analysis of real-world data. Biomarkers in Medicine, 2017, 11, 751-760.	1.4	33
29	Pathways towards indolent B-cell lymphoma â€" Etiology and therapeutic strategies. Blood Reviews, 2017, 31, 426-435.	5.7	7
30	Multispectral imaging for highly accurate analysis of tumourâ€infiltrating lymphocytes in primary melanoma. Histopathology, 2017, 70, 643-649.	2.9	14
31	Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma. Leukemia, 2017, 31, 625-636.	7.2	47
32	Integration of next-generation sequencing in clinical diagnostic molecular pathology laboratories for analysis of solid tumours; an expert opinion on behalf of IQN Path ASBL. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 470, 5-20.	2.8	82
33	Targeting the environment. Journal of Hematopathology, 2017, 10, 47-47.	0.4	0
34	New developments in the pathology of malignant lymphoma. A review of the literature published from Septemberâ€"August 2017. Journal of Hematopathology, 2017, 10, 117-127.	0.4	3
35	Editorial: when to be an author?. Journal of Hematopathology, 2017, 10, 89-90.	0.4	1
36	High mRNA expression of splice variant SYK short correlates with hepatic disease progression in chemonaive lymph node negative colon cancer patients. PLoS ONE, 2017, 12, e0185607.	2.5	14

#	Article	IF	Citations
37	Direct inhibition of STAT signaling by platinum drugs contributes to their anti-cancer activity. Oncotarget, 2017, 8, 54434-54443.	1.8	13
38	Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma. Oncotarget, 2016, 7, 2401-2416.	1.8	93
39	ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Annals of Oncology, 2016, 27, 1386-1422.	1.2	2,545
40	Are we making progress?. Journal of Hematopathology, 2016, 9, 51-51.	0.4	1
41	Quality to rely on: meeting report of the 5th Meeting of External Quality Assessment, Naples 2016. ESMO Open, 2016, 1, e000114.	4.5	6
42	Clinical and Biologic Significance of MYC Genetic Mutations in De Novo Diffuse Large B-cell Lymphoma. Clinical Cancer Research, 2016, 22, 3593-3605.	7.0	48
43	The Role of Dectin-2 for Host Defense Against Disseminated Candidiasis. Journal of Interferon and Cytokine Research, 2016, 36, 267-276.	1.2	45
44	T-cell Landscape in a Primary Melanoma Predicts the Survival of Patients with Metastatic Disease after Their Treatment with Dendritic Cell Vaccines. Cancer Research, 2016, 76, 3496-3506.	0.9	33
45	New developments in the pathology of malignant lymphoma. A review of the literature published from Januaryâ€“April 2016. Journal of Hematopathology, 2016, 9, 73-83.	0.4	3
46	Histopathological, Molecular, and Genetic Profile of Hereditary Diffuse Gastric Cancer: Current Knowledge and Challenges for the Future. Advances in Experimental Medicine and Biology, 2016, 908, 371-391.	1.6	47
47	New developments in the pathology of malignant lymphoma: a review of the literature published from Juneâ€“August 2016. Journal of Hematopathology, 2016, 9, 129-134.	0.4	2
48	Open access and data. Journal of Hematopathology, 2016, 9, 105-105.	0.4	0
49	We need to be (much) better. Journal of Hematopathology, 2016, 9, 1-1.	0.4	0
50	How we do: optimizing bone marrow biopsy logistics for sign-out within 2Âdays. Journal of Hematopathology, 2016, 9, 67-71.	0.4	2
51	New developments in the pathology of malignant lymphoma. A review of the literature published from September 2015â€“December 2015. Journal of Hematopathology, 2016, 9, 19-27.	0.4	3
52	Clinical features of patients with nodal marginal zone lymphoma compared to follicular lymphoma: similar presentation, but differences in prognostic factors and rate of transformation. Leukemia and Lymphoma, 2016, 57, 1649-1656.	1.3	13
53	RAS testing in metastatic colorectal cancer: advances in Europe. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 468, 383-396.	2.8	27
54	A 20-year population-based study on the epidemiology, clinical features, treatment, and outcome of nodular lymphocyte predominant Hodgkin lymphoma. Annals of Hematology, 2016, 95, 417-423.	1.8	18

#	Article	IF	Citations
55	Three Rounds of External Quality Assessment in France to Evaluate the Performance of 28 Platforms for Multiparametric Molecular Testing in Metastatic Colorectal and Non-Small Cell Lung Cancer. Journal of Molecular Diagnostics, 2016, 18, 205-214.	2.8	23
56	A subset of low-grade B cell lymphomas with a follicular growth pattern but without a BCL2 translocation shows features suggestive of nodal marginal zone lymphoma. Journal of Hematopathology, 2016, 9, 3-8.	0.4	7
57	Tetraspanin CD37 protects against the development of B cell lymphoma. Journal of Clinical Investigation, 2016, 126, 653-666.	8.2	47
58	p63 expression confers significantly better survival outcomes in high-risk diffuse large B-cell lymphoma and demonstrates p53-like and p53-independent tumor suppressor function. Aging, 2016, 8, 345-365.	3.1	19
59	RelA NF-Î²B subunit activation as a therapeutic target in diffuse large B-cell lymphoma. Aging, 2016, 8, 3321-3340.	3.1	29
60	Improving hospital care for patients with non-Hodgkin's lymphomas.. Journal of Clinical Oncology, 2016, 34, 6593-6593.	1.6	0
61	Identification of IG-clonality status as a pre-treatment predictor for mortality in patients with immunodeficiency-associated Epstein-Barr virus-related lymphoproliferative disorders. Haematologica, 2015, 100, e152-e154.	3.5	2
62	The folly of impact factors: some solutions. Journal of Hematopathology, 2015, 8, 49-49.	0.4	0
63	We are not our genes. Journal of Hematopathology, 2015, 8, 201-202.	0.4	0
64	Reduced Circumferential Resection Margin Involvement in Rectal Cancer Surgery: Results of the Dutch Surgical Colorectal Audit. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 1111-1119.	4.9	19
65	Panitumumab Use in Metastatic Colorectal Cancer and Patterns of KRAS Testing: Results from a Europe-Wide Physician Survey and Medical Records Review. PLoS ONE, 2015, 10, e0140717.	2.5	9
66	Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma. Oncotarget, 2015, 6, 5597-5614.	1.8	61
67	New developments in the pathology of malignant lymphoma: a review of the literature published from May 2015â€“September 2015. Journal of Hematopathology, 2015, 8, 225-234.	0.4	2
68	Immunohistochemical differentiation between follicular lymphoma and nodal marginal zone lymphoma - combined performance of multiple markers. Haematologica, 2015, 100, e358-e360.	3.5	20
69	Gastric cancer in three relatives of a patient with a biallelic IL12RB1 mutation. Familial Cancer, 2015, 14, 89-94.	1.9	14
70	Epsteinâ€“Barr Virus in Inflammatory Bowel Disease: The Spectrum of Intestinal Lymphoproliferative Disorders. Journal of Crohn's and Colitis, 2015, 9, 398-403.	1.3	70
71	Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline‹i›CDH1‹/i›mutation carriers. Journal of Medical Genetics, 2015, 52, 361-374.	3.2	479
72	Trends in quality of non-Hodgkinâ€™s lymphoma care: is it getting better?. Annals of Hematology, 2015, 94, 1195-1203.	1.8	3

#	Article	IF	Citations
73	The folly of impact factors. Journal of Hematopathology, 2015, 8, 1-1.	0.4	0
74	A germline homozygous mutation in the base-excision repair gene NTHL1 causes adenomatous polyposis and colorectal cancer. Nature Genetics, 2015, 47, 668-671.	21.4	311
75	New developments in the pathology of malignant lymphoma: a review of the literature published from October 2014â€“December 2014. Journal of Hematopathology, 2015, 8, 21-29.	0.4	1
76	New developments in the pathology of malignant lymphoma: a review of literature published from January 2015 to April 2015. Journal of Hematopathology, 2015, 8, 71-79.	0.4	2
77	Variation in guideline adherence in non-Hodgkinâ€™s lymphoma care: impact of patient and hospital characteristics. BMC Cancer, 2015, 15, 578.	2.6	6
78	Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Modern Pathology, 2015, 28, 1555-1573.	5.5	48
79	Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy. Modern Pathology, 2015, 28, 1297-1314.	5.5	21
80	The homogeneous mutation status of a 22 gene panel justifies the use of serial sections of colorectal cancer tissue for external quality assessment. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2015, 467, 273-278.	2.8	11
81	Paediatric hematopathology: something real special. Journal of Hematopathology, 2015, 8, 99-99.	0.4	0
82	Immunoglobulin rearrangement analysis from multiple lesions in the same patient using nextâ€generation sequencing. Histopathology, 2015, 67, 843-858.	2.9	5
83	Evaluation of NF-ÎºB subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions. Modern Pathology, 2015, 28, 1202-1213.	5.5	17
84	Lymphocytic variant hypereosinophilic syndrome progressing to angioimmunoblastic T-cell lymphoma. Leukemia and Lymphoma, 2015, 56, 1891-1894.	1.3	14
85	External Quality Assessment Unravels Interlaboratory Differences in Quality of RAS Testing for Antiâ€EGFR Therapy in Colorectal Cancer. Oncologist, 2015, 20, 257-262.	3.7	39
86	Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries. Oncotarget, 2015, 6, 5615-5633.	1.8	72
87	RAS testing in metastatic colorectal cancer: excellent reproducibility amongst 17 Dutch pathology centers. Oncotarget, 2015, 6, 15681-15689.	1.8	12
88	Prognostic impact of c-Rel nuclear expression and REL amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma. Oncotarget, 2015, 6, 23157-23180.	1.8	35
89	Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma-is it necessary?. Oncotarget, 2015, 6, 13933-13945.	1.8	33
90	Awareness of KRAS testing by oncologists and panitumumab use in colorectal cancer patients: A European survey.. Journal of Clinical Oncology, 2015, 33, 547-547.	1.6	0

#	Article	IF	Citations
91	New developments in the pathology of malignant lymphoma. A review of the literature published from Juneâ€“August 2014. Journal of Hematopathology, 2014, 7, 103-108.	0.4	0
92	Lymphomas in Istanbul. Journal of Hematopathology, 2014, 7, 145-145.	0.4	0
93	Evaluation of a panel of expert pathologists: review of the diagnosis and histological classification of Hodgkin and non-Hodgkin lymphomas in a population-based cancer registry. Leukemia and Lymphoma, 2014, 55, 1018-1022.	1.3	11
94	New and old questions. Journal of Hematopathology, 2014, 7, 93-93.	0.4	0
95	Role of Dectin-2 for Host Defense against Systemic Infection with Candida glabrata. Infection and Immunity, 2014, 82, 1064-1073.	2.2	100
96	Neoadjuvant Sorafenib Treatment of Clear Cell Renal Cell Carcinoma and Release of Circulating Tumor Fragments. Neoplasia, 2014, 16, 221-228.	5.3	18
97	Editorial for the Journal of Hematopathology: crisis in science?. Journal of Hematopathology, 2014, 7, 1-1.	0.4	0
98	New developments in the pathology of malignant lymphoma. A review of the literature published from August 2013 to December 2013. Journal of Hematopathology, 2014, 7, 15-25.	0.4	0
99	Sequential immunohistochemistry: a promising new tool for the pathology laboratory. Histopathology, 2014, 65, 651-657.	2.9	44
100	Prevalence and Clinical Implications of Epsteinâ€“Barr Virus Infection in De Novo Diffuse Large B-Cell Lymphoma in Western Countries. Clinical Cancer Research, 2014, 20, 2338-2349.	7.0	117
101	Grey zone lymphomas. Journal of Hematopathology, 2014, 7, 47-47.	0.4	0
102	HNF4A immunohistochemistry facilitates distinction between primary and metastatic breast and gastric carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 464, 673-679.	2.8	26
103	Limited diagnostic value of microsatellite instability associated pathology features in colorectal cancer. Familial Cancer, 2014, 13, 351-359.	1.9	3
104	Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Modern Pathology, 2014, 27, 958-971.	5.5	112
105	Clinical Implications of Phosphorylated STAT3 Expression in De Novo Diffuse Large B-cell Lymphoma. Clinical Cancer Research, 2014, 20, 5113-5123.	7.0	60
106	Prevalence and clinical implications of cyclin D1 expression in diffuse large Bâ€cell lymphoma (DLBCL) treated with immunochemotherapy: A report from the International DLBCL RituximabâCHOP Consortium Program. Cancer, 2014, 120, 1818-1829.	4.1	32
107	Higher Quality of Molecular Testing, an Unfulfilled Priority. Journal of Molecular Diagnostics, 2014, 16, 371-377.	2.8	22
108	To publish or perish. Journal of Hematopathology, 2013, 6, 55-55.	0.4	0

#	Article	IF	Citations
109	Precision medicine. Journal of Hematopathology, 2013, 6, 1-1.	0.4	3
110	The ileo neo rectal anastomosis: long-term results of surgical innovation in patients after ulcerative colitis and familial adenomatous polyposis. International Journal of Colorectal Disease, 2013, 28, 111-118.	2.2	5
111	Cancer, or not. Journal of Hematopathology, 2013, 6, 119-119.	0.4	0
112	Trends in incidence, therapy and outcome of localized nodal and extranodal marginal zone lymphomas: declining incidence and inferior outcome for gastrointestinal sites. Leukemia and Lymphoma, 2013, 54, 1891-1897.	1.3	17
113	Guideline on the requirements of external quality assessment programs in molecular pathology. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2013, 462, 27-37.	2.8	70
114	KRAS mutation analysis on low percentage of colon cancer cells: the importance of quality assurance. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2013, 462, 39-46.	2.8	26
115	MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood, 2013, 121, 4021-4031.	1.4	596
116	CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Blood, 2013, 121, 2715-2724.	1.4	206
117	The evaluation of colon biopsies using virtual microscopy is reliable. Histopathology, 2013, 63, 114-121.	2.9	23
118	Diagnosing and classifying malignant lymphomas is improved by referring cases to a panel of expert pathologists. Journal of Hematopathology, 2013, 6, 179-185.	0.4	1
119	Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study. Haematologica, 2013, 98, 255-263.	3.5	142
120	Recognizing nodal marginal zone lymphoma: recent advances and pitfalls. A systematic review. Haematologica, 2013, 98, 1003-1013.	3.5	85
121	T(14;18)(q32;q21) involving MALT1 and IGH genes occurs in extranodal diffuse large B-cell lymphomas of the breast and testis. Modern Pathology, 2013, 26, 421-427.	5.5	20
122	European Consensus Conference for external quality assessment in molecular pathology. Annals of Oncology, 2013, 24, 1958-1963.	1.2	39
123	Undertreatment of patients with localized extranodal compared with nodal diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2013, 54, 1698-1705.	1.3	7
124	Single nucleotide variation in the TP53 3â€² untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program. Blood, 2013, 121, 4529-4540.	1.4	41
125	What we talk about when we talk about T-cell lymphomas. Journal of Hematopathology, 2012, 5, 289-289.	0.4	0
126	Centralised multidisciplinary re-evaluation of diagnostic procedures in patients with newly diagnosed Hodgkin lymphoma. Annals of Oncology, 2012, 23, 2676-2681.	1.2	10

#	Article	IF	Citations
127	Higher cytoplasmic and nuclear poly(ADP-ribose) polymerase expression in familial than in sporadic breast cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2012, 461, 425-431.	2.8	4
128	Application of Microfluidic Technology to the BIOMED-2 Protocol for Detection of B-Cell Clonality. Journal of Molecular Diagnostics, 2012, 14, 30-37.	2.8	21
129	Do Pre-Analytical Parameters Explain KRAS Test Sensitivity Disparities?. Journal of Molecular Diagnostics, 2012, 14, 631-633.	2.8	2
130	Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Leukemia, 2012, 26, 2103-2113.	7.2	301
131	Welcome to Lisbon!. Journal of Hematopathology, 2012, 5, 105-105.	0.4	0
132	New developments in the pathology of malignant lymphoma. A review of the literature published from January 2012â€“July 2012. Journal of Hematopathology, 2012, 5, 149-157.	0.4	0
133	Familial gastric cancer: guidelines for diagnosis, treatment and periodic surveillance. Familial Cancer, 2012, 11, 363-369.	1.9	71
134	Clinical and pathological features of testicular diffuse large B-cell lymphoma: a heterogeneous disease. Leukemia and Lymphoma, 2012, 53, 242-246.	1.3	14
135	Molecular pathogenesis and histologic and clinical features of extranodal marginal zone lymphomas of mucosa-associated lymphoid tissue type. Leukemia and Lymphoma, 2012, 53, 1032-1045.	1.3	18
136	Implementation of Formalin-Fixed, Paraffin-Embedded Cell Line Pellets as High-Quality Process Controls in Quality Assessment Programs for KRAS Mutation Analysis. Journal of Molecular Diagnostics, 2012, 14, 187-191.	2.8	13
137	CDH1â€related hereditary diffuse gastric cancer syndrome: Clinical variations and implications for counseling. International Journal of Cancer, 2012, 131, 367-376.	5.1	110
138	Psychological distress in newly diagnosed colorectal cancer patients following microsatellite instability testing for Lynch syndrome on the pathologistâ€™s initiative. Familial Cancer, 2012, 11, 259-267.	1.9	16
139	A practical approach to diagnostic Ig/TCR clonality evaluation in clinical pathology. Journal of Hematopathology, 2012, 5, 17-25.	0.4	12
140	Editorial: the second special issue of the Journal of Hematopathology. Journal of Hematopathology, 2012, 5, 1-1.	0.4	0
141	Clonality testing: teamwork by pathologist and molecular biologist. Journal of Hematopathology, 2012, 5, 3-5.	0.4	0
142	The times have changed: molecular pathology is here to stay. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2012, 460, 129-130.	2.8	3
143	Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study. Lancet Oncology, The, 2011, 12, 49-55.	10.7	232
144	Preparing pathology for personalized medicine: possibilities for improvement of the pre-analytical phase. Histopathology, 2011, 59, 1-7.	2.9	44

#	Article	IF	Citations
145	Inter-observer variation in the histological diagnosis of polyps in colorectal cancer screening. Histopathology, 2011, 58, 974-981.	2.9	46
146	Cancer risk in patients with Noonan syndrome carrying a PTPN11 mutation. European Journal of Human Genetics, 2011, 19, 870-874.	2.8	141
147	KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. British Journal of Cancer, 2011, 104, 1020-1026.	6.4	262
148	Variation in Lymph Node Evaluation in Rectal Cancer: A Dutch Nationwide Population-Based Study. Annals of Surgical Oncology, 2011, 18, 386-395.	1.5	21
149	Mutation analysis of KRAS prior to targeted therapy in colorectal cancer: development and evaluation of quality by a European external quality assessment scheme. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2011, 459, 155-160.	2.8	18
150	The times they are a-changin'. Journal of Hematopathology, 2011, 4, 1-1.	0.4	0
151	New developments in the pathology of malignant lymphoma: a review of the literature published from November 2010â€“January 2011. Journal of Hematopathology, 2011, 4, 31-43.	0.4	0
152	High prevalence of adverse prognostic genetic aberrations and unmutated IGHV genes in small lymphocytic lymphoma as compared to chronic lymphocytic leukemia. Journal of Hematopathology, 2011, 4, 189-197.	0.4	2
153	Crisis? What crisis?. Journal of Hematopathology, 2011, 4, 133-133.	0.4	0
154	New developments in the pathology of malignant lymphoma. A review of the literature published from February 2011 to August 2011. Journal of Hematopathology, 2011, 4, 135-144.	0.4	0
155	Rising costs of health care and pathology: cause or solution?. Journal of Hematopathology, 2011, 4, 185-185.	0.4	0
156	Recurrence and variability of germline EPCAM deletions in Lynch syndrome. Human Mutation, 2011, 32, 407-414.	2.5	137
157	Identification of candidate predisposing copy number variants in familial and earlyâ€onset colorectal cancer patients. International Journal of Cancer, 2011, 129, 1635-1642.	5.1	66
158	Cellular angiofibroma: analysis of 25 cases emphasizing its relationship to spindle cell lipoma and mammary-type myofibroblastoma. Modern Pathology, 2011, 24, 82-89.	5.5	159
159	External Quality Assessment for KRAS Testing Is Needed: Setup of a European Program and Report of the First Joined Regional Quality Assessment Rounds. Oncologist, 2011, 16, 467-478.	3.7	83
160	Large variation between hospitals and pathology laboratories in lymph node evaluation in colon cancer and its impact on survival, a nationwide population-based study in The Netherlands. Annals of Oncology, 2011, 22, 110-117.	1.2	39
161	Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice. Journal of Clinical Investigation, 2011, 121, 3100-3108.	8.2	271
162	Overlap, Common Features, and Essential Differences in Pediatric Granulomatous Inflammatory Bowel Disease. Journal of Pediatric Gastroenterology and Nutrition, 2010, 51, 690-697.	1.8	56

#	Article	IF	Citations
163	Are we making progress?. Journal of Hematopathology, 2010, 3, 59-59.	0.4	0
164	New developments in the pathology of malignant lymphoma. A review of the literature published from August 2010â€“October 2010. Journal of Hematopathology, 2010, 3, 167-174.	0.4	0
165	Use of RNA Electroporated DC for Activation of LRH-1 Specific Cytotoxic T Lymphocytes in the Treatment of Lymphoid Malignancies.. Blood, 2006, 108, 138-138.	1.4	1